ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
|
|
- Adela Bond
- 5 years ago
- Views:
Transcription
1 ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA mg 120 ORAL Alemtuzumab Alemtuzumab Anastrozole STRADEXA mg 30 ORAL Anastrozole TEVA ANASTROZOLE mg 30 ORAL Anastrozole ACCORD ANASTROZOLE mg 30 ORAL Bendamustine RIBOMUSTIN mg 1 INJ Bendamustine RIBOMUSTIN mg 1 INJ Bevacizumab AVASTIN mg 1 INJ Bevacizumab AVASTIN mg 1 INJ Bicalutamide CALOXA mg 30 ORAL Bicalutamide SPEC-BICALUTAMIDE mg 30 ORAL Bicalutamide ACCORD BICALUTAMIDE mg 30 ORAL Bicalutamide TEVA BICALUTAMIDE mg 30 ORAL Bicalutamide ANANDROCA mg 30 ORAL Bicalutamide BICALOX mg 30 ORAL Bleomycin Bleolem IU 1 INJ Bortezomib VALTIB mg 1 INJ Bortezomib VELCADE mg 1 INJ Buserelin SUPREFACT 3 MONTH DEPOT mg 1 IMP Cabazitaxel CABITAS mg 1 INJ Capecitabine PECASET mg 60 ORAL Capecitabine CAPEXA mg 60 ORAL Capecitabine CAPECITABINE SPECPHARM mg 60 ORAL Capecitabine XELODA mg 60 ORAL Capecitabine PECASET mg 120 ORAL Capecitabine CAPEXA mg 120 ORAL Capecitabine CAPECITABINE SPECPHARM mg 120 ORAL Capecitabine XELODA mg 120 ORAL Carboplatin Accord Carboplatin mg 1 INJ Carboplatin Carbosin mg 1 INJ Carboplatin ASPEN CARBOPLATIN mg 1 INJ Carboplatin Accord Carboplatin mg 1 INJ Manufacturer JANSSEN PHARMACEUTICALS ASTELLAS PHARMA ASTELLAS PHARMA SPECPHARM (PTY) LTD ZYDUS CADILA PHARMAPLAN JANSSEN PHARMACEUTICALS SPECPHARM (PTY) LTD SPECPHARM (PTY) LTD
2 Carboplatin Carbosin mg 1 INJ Carboplatin ASPEN CARBOPLATIN mg 1 INJ Carboplatin Carbosin mg 1 INJ Cetuximab ERBITUX mg 1 INJ Chlorambucil LEUKERAN mg 25 ORAL Cisplatin CISACOR mg 1 INJ Cisplatin P&U CISPLATIN mg 1 INJ Cisplatin CISACOR mg 1 INJ Cisplatin P&U CISPLATIN mg 1 INJ Cyclophosphamide ENDOXAN mg 1 INJ Cyclophosphamide ENDOXAN mg 1 INJ Cyclophosphamide ENDOXAN mg 50 ORAL Cyproterone CIPLA-CYPROTERONE ACETATE mg 20 ORAL Cytarabine CYTOSAR mg 1 INJ Cytarabine LARACIT mg 1 INJ Dacarbazine DACIN mg 1 INJ Dactinomycin Dasatinib SPRYCEL mg 60 ORAL Dasatinib SPRYCEL mg 60 ORAL Dasatinib SPRYCEL mg 60 ORAL Dasatinib SPRYCEL mg 30 ORAL Daunorubicin DAUNOBLASTIN mg 1 INJ Docetaxel ERIOX mg 1 INJ Docetaxel KEY DOCETAXEL AND DILUENT mg 1 INJ Docetaxel DOCETAXEL ACCORD mg 1 INJ Docetaxel CIPLA-DOCETAXEL mg 1 INJ Docetaxel ERIOX mg 1 INJ Docetaxel KEY DOCETAXEL AND DILUENT mg 1 INJ Docetaxel DOCETAXEL ACCORD mg 1 INJ Docetaxel CIPLA-DOCETAXEL mg 1 INJ Docetaxel DOCETAXEL ACCORD mg 1 INJ Doxorubicin DOXORUBICIN RTU mg 1 INJ Doxorubicin RUBEXET mg 1 INJ Doxorubicin Cipla-Doxorubicin mg 1 INJ Doxorubicin DOXORUBICIN ACCORD mg 1 INJ Doxorubicin DOXORUBICIN RTU mg 1 INJ Doxorubicin RUBEXET mg 1 INJ Doxorubicin Cipla-Doxorubicin mg 1 INJ Doxorubicin DOXORUBICIN ACCORD mg 1 INJ Doxorubicin RUBEXET mg 1 INJ MERCK
3 Enzalutamide XTANDI mg 112 ORAL Epirubicin EPICORD mg 1 INJ Epirubicin Accord Epirubicin mg 1 INJ Epirubicin ASPEN EPIRUBICIN mg 1 INJ Epirubicin EPICORD mg 1 INJ Epirubicin Accord Epirubicin mg 1 INJ Epirubicin ASPEN EPIRUBICIN mg 1 INJ Epirubicin ASPEN EPIRUBICIN mg 1 INJ Eribulin HALAVEN mg 1 INJ Erlotinib TARCEVA mg 30 ORAL Erlotinib TARCEVA mg 30 ORAL Erlotinib TARCEVA mg 30 ORAL Etoposide EPOSIN mg 1 INJ Etoposide ASPEN ETOPOSIDE mg 1 INJ Etoposide oral Everolimus AFINITOR mg 30 ORAL Everolimus AFINITOR mg 30 ORAL Everolimus AFINITOR mg 30 ORAL Exemestane EXICAN mg 30 ORAL Exemestane EQUISIN mg 30 ORAL Exemestane ASPEN EXEMESTANE mg 30 ORAL Filgrastim FILGRASTIM TEVA MIU 5 INJ Filgrastim Neupogen Pref Syr MIU 5 INJ Fludarabine TEVA FLUDARABINE mg 1 INJ Fludarabine Fludara mg 5 INJ Fludarabine FLUDARA ORAL mg 20 ORAL Fluorouracil FLORACOR mg 1 INJ Fluorouracil FLURACEDYL mg 1 INJ Fluorouracil Fluracedyl mg 1 INJ Flutamide FLUTAPLEX mg 90 ORAL Fulvestrant FASLODEX mg 2 INJ Gemcitabine CYTIGEM mg 1 INJ Gemcitabine ACCORD GEMCITABINE mg 1 INJ Gemcitabine GEMCITABINE mg 1 INJ Gemcitabine ONCOGEM mg 1 INJ Gemcitabine CYTIGEM mg 1 INJ Gemcitabine ACCORD GEMCITABINE mg 1 INJ Gemcitabine GEMCITABINE mg 1 INJ Gemcitabine ONCOGEM mg 1 INJ Goserelin ZOLADEX DEPOT mg 1 INJ ASTELLAS PHARMA EQUITY PHARMACEUTICALS EQUITY PHARMACEUTICALS AMGEN ASTRAZENECA ASTRAZENECA
4 Goserelin ZOLADEX DEPOT mg 1 INJ Hydroxyurea HYDREA mg 100 ORAL Idarubicin ZAVEDOS mg 1 INJ Idarubicin ZAVEDOS mg 1 INJ Ifosfamide HOLOXAN mg 1 INJ Ifosfamide HOLOXAN mg 1 INJ Ifosfamide HOLOXAN mg 1 INJ Imatinib SUNMATIN mg 60 ORAL Imatinib MIVESTA mg 60 ORAL Imatinib IMAVEC mg 60 ORAL Imatinib IMATINIB ACCORD mg 60 ORAL Imatinib VATIVIO mg 120 ORAL Imatinib SUNMATIN mg 30 ORAL Imatinib MIVESTA mg 30 ORAL Imatinib IMAVEC mg 30 ORAL Imatinib IMATINIB ACCORD mg 30 ORAL Interferon alfa-2a Interferon alfa-2b Irinotecan IRINOTAS mg 1 INJ Irinotecan ACCORD IRINOTECAN mg 1 INJ Irinotecan CIPLA-IRINOTECAN mg 1 INJ Irinotecan IRINOTECAN mg 1 INJ Irinotecan IRINOTAS mg 1 INJ Irinotecan ACCORD IRINOTECAN mg 1 INJ Irinotecan CIPLA-IRINOTECAN mg 1 INJ Irinotecan IRINOTECAN mg 1 INJ Ketoconazole KETAZOL mg 10 ORAL Ketoconazole KETAZOL mg 30 ORAL Lanreotide SOMATULINE AUTOGEL mg 1 INJ Lanreotide SOMATULINE AUTOGEL mg 1 INJ Lanreotide SOMATULINE AUTOGEL mg 1 INJ Lapatinib TYKERB mg 70 ORAL Letrozole LARADEX mg 30 ORAL Letrozole CIPLA-LETROZOLE mg 30 ORAL Letrozole FEMZOLE mg 30 ORAL Letrozole ACCORD LETROZOLE mg 30 ORAL Leuprorelin LUCRIN DEPOT S/DOSE mg 1 INJ Leuprorelin LUCRIN VIAL mg 1 INJ Leuprorelin Hexal LEUPROLIDE HEXAL mg 1 IMP Leuprorelin with Atrigel ELIGARD mg 1 INJ ASTRAZENECA ADCOCK INGRAM CRITICAL CARE ABBVIE PTY LTD ABBVIE PTY LTD
5 Leuprorelin with Atrigel ELIGARD mg 1 INJ Leuprorelin with Atrigel ELIGARD mg 1 INJ Liposomal Doxorubicin DOXOLIP (10 ml) mg 1 INJ Liposomal Doxorubicin DOXOPEG mg 1 INJ Lomustine 10 Lomustine 40 Medroxyprogesterone PROVERA mg 100 ORAL Medroxyprogesterone PROVERA mg 100 ORAL Melphalan ALKERAN mg 1 INJ Melphalan ALKERAN mg 25 ORAL Methotrexate METHACOR mg 1 INJ Methotrexate ABITREXATE mg 1 INJ Methotrexate ABITREXATE VIAL 20ML mg 1 INJ Methotrexate ABITREXATE mg 1 INJ Methotrexate ABITREXATE mg 1 INJ Methotrexate ABITREXATE mg 100 ORAL Mitomycin MITOMYCIN-C mg 1 INJ Mitomycin MITOMYCIN-C mg 1 INJ Mitoxantrone MITOXANTRONE-HEXAL mg 1 INJ Nilotinib TASIGNA mg 112 ORAL Nilotinib TASIGNA mg 112 ORAL Octreotide SANDOSTATIN mg 5 INJ Octreotide SANDOSTATIN mg 5 INJ Octreotide SANDOSTATIN mg 1 INJ Octreotide SANDOSTATIN LAR PREFILL mg 1 INJ Octreotide SANDOSTATIN LAR PREFILL mg 1 INJ Octreotide SANDOSTATIN LAR PREF mg 1 INJ Oxaliplatin INTAS OXALIPLATIN mg 1 INJ Oxaliplatin OXALIPLATIN KEY mg 1 INJ Oxaliplatin OPLAXIN mg 1 INJ Oxaliplatin OXALIPLATIN PCH mg 1 INJ Oxaliplatin OXALIWIN RTU mg 1 INJ Oxaliplatin INTAS OXALIPLATIN mg 1 INJ Oxaliplatin OXALIPLATIN KEY mg 1 INJ Oxaliplatin OPLAXIN mg 1 INJ Oxaliplatin OXALIPLATIN PCH mg 1 INJ Oxaliplatin OXALIWIN RTU mg 1 INJ Paclitaxel ACCORD PACLITAXEL mg 1 INJ Paclitaxel PCH-PACLITAXEL mg 1 INJ Paclitaxel CIPLA-PACLITAXEL mg 1 INJ ZENTIVA SOUTH AFRICA PTY LTD ZENTIVA SOUTH AFRICA PTY LTD
6 Paclitaxel ACCORD PACLITAXEL mg 1 INJ Paclitaxel PCH-PACLITAXEL mg 1 INJ Paclitaxel CIPLA-PACLITAXEL mg 1 INJ Paclitaxel ACCORD PACLITAXEL mg 1 INJ Paclitaxel CIPLA-PACLITAXEL mg 1 INJ Paclitaxel PCH-PACLITAXEL mg 1 INJ Pazopanib VOTRIENT mg 30 ORAL Pazopanib VOTRIENT mg 30 ORAL Pemetrexed PEMETREXED ACCORD mg 1 INJ Rituximab MABTHERA mg 2 INJ Rituximab MABTHERA mg 1 INJ Sorafenib NEXAVAR mg 60 ORAL Streptozocin Sunitinib SUTENT mg 28 ORAL Sunitinib SUTENT mg 28 ORAL Sunitinib SUTENT mg 28 ORAL Tamoxifen KESSAR mg 30 ORAL Tamoxifen TAMOXIHEXAL mg 30 ORAL Tamoxifen TAMOPLEX mg 30 ORAL Tamoxifen NEOPHEDAN mg 30 ORAL Temozolomide TEMINTAS mg 5 ORAL Temozolomide ACCORD TEMOZOLOMIDE mg 5 ORAL Temozolomide TEMODAL mg 5 ORAL Temozolomide TEMINTAS mg 5 ORAL Temozolomide ACCORD TEMOZOLOMIDE mg 5 ORAL Temozolomide TEMODAL mg 5 ORAL Temozolomide TEMINTAS mg 5 ORAL Temozolomide ACCORD TEMOZOLOMIDE mg 5 ORAL Temozolomide TEMODAL mg 5 ORAL Temozolomide TEMODAL mg 5 ORAL Temozolomide TEMODAL mg 5 ORAL Temozolomide TEMINTAS mg 5 ORAL Temozolomide ACCORD TEMOZOLOMIDE mg 5 ORAL Temozolomide TEMODAL mg 5 ORAL Thalidomide THALIDOMIDE CELGENE mg 28 ORAL Topotecan HYCAMTIN mg 5 INJ Topotecan HYCAMTIN mg 10 ORAL Topotecan HYCAMTIN mg 10 ORAL Trastuzumab HERCEPTIN MULTIDOSE mg 1 INJ Trastuzumab HERCEPTIN SC mg 1 INJ BAYER PHARMA GLAXO SMITHKLINE
7 Vinblastine VINBLASTINE TEVA mg 1 INJ Vincristine P&U VINCRISTINE CSV mg 5 INJ Vincristine Accord Vincristine mg 1 INJ Vinorelbine VINORELBINE mg 1 INJ Vinorelbine NAVELBINE mg 10 INJ Vinorelbine VINORELBINE mg 1 INJ Vinorelbine NAVELBINE mg 10 INJ Vinorelbine NAVELBINE ORAL mg 1 ORAL Vinorelbine NAVELBINE ORAL mg 1 ORAL Zoledronic Acid ZOMEDRON mg 1 INJ Zoledronic Acid ZOBONE mg 1 INJ Zoledronic Acid ZOMABON mg 1 INJ ACTOR PHARMA
MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
More informationFormulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationChemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationObjective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
More informationFREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK
Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationHCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationAnastrozole. Active Ingredient. Brand Name: Arimidex Strength: 1 mg Dosage Form: Tablets Pack Size: 28 Tabs Company: AstraZeneca
Super Specialty Drugs by Anastrozole Arimidex 1 mg 28 Tabs AstraZeneca Armotraz 1 mg 10 Tabs Cipla Anastrozole Anabrez 1 mg 100 Tabs Sun Decitabine Dacogen 50 mg 1 Vial Eisai Inc. Erlotinib Erlocip-150
More informationBladder Cancer (Urothelial) Pathways
Bladder Cancer (Urothelial) Pathways Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationBladder Cancer Pathways (Urothelial)
Bladder Cancer Pathways (Urothelial) Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More information1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000
ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationPart B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationIntroduction to Antineoplastic Prescribing
Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationWho is Bearing the Cost?
THE COS ST T OF CANCE R DRUGS IN CANADA PA R T 2 Who is Bearing the Cost? KONG KHOO, ROSEMARY COLUCCI, WILLIAM HRYNIUK, ROBERT KAMINO, TANIA REDINA AND COLLEEN SAVAGE Introduction Last year we reported
More informationRegimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.
Palliative Breast Cancer Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for breast cancer used in the palliative setting. It is expected that the prescribing oncologist
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationAn introduction to the Essential Medicines concept: balancing innovation with public health priorities
An introduction to the Essential Medicines concept: balancing innovation with public health priorities WHO HQ, Geneva 11 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the Selection and
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationOverview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)
Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More informationREGULATORY INFORMATION
REGULATORY*INFORMATION/*CANCER*MEDICINES* Summary'of'regulatory'status'of'the'medicines' As#recommended#in#the#EML#Secretariat s#instructions#regarding#applications#for#the#addition#of#new# medicines#
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationInterChina Insight. Partnering up to fight cancer. Strategies for the China oncology market. InterChina Consulting. By Rick Woo April 03, 2013
Strategies for the China oncology market By Rick Woo InterChina Consulting 英特华投资咨询有限公司 Beijing Shanghai Madrid Washington DC Strategy M&A Advisory IMAP China 2013 InterChina Consulting All Rights Reserved
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More informationOvarian Cancer. compendia TREATMENT OF
drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationDRUG PROPERTIES YOU NEED TO KNOW
jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 8 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class b. resistance 2. Pharmacokinetics 3. Therapeutic uses 4. Major side effects/toxicities
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationNorth of England Cancer Drugs Approval Group (NECDAG) Cumulative Table of Decisions August 2012
Notes: This document is updated every 2 to 3 months; please check our website www.cancernorth.nhs.uk for latest version. This document does not all contain Interim Cancer Drugs Fund s, i.e. decisions made
More informationHazard Meds: Navigating the Warning Beacons
Hazard Meds: Navigating the Warning Beacons Disclosures I have nothing to disclose at this time. Mark Twohey, Pharm.D., BCOP Palmetto Health Richland March 24, 2012 Objectives Understand the reasons for
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Characterization of the generated hipsc lines a) Western blot analysis indicating the efficient downregulation of p53 upon knockdown in three hipsc lines (
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationCANCER PREVENTION AND ACCESS TO MEDICINES. Gracemarie Bricalli ESMO Head of International Affairs
CANCER PREVENTION AND ACCESS TO MEDICINES Gracemarie Bricalli ESMO Head of International Affairs ESMO s 2020 Vision: Access to cancer care ESMO s 2020 vision statement recognises that progress in the management
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationDRUGS YOU NEED TO KNOW
jfitzake@d.umn.edu Page 1 of 7 DRUGS YOU NEED TO KNOW ALKYLATING AGENTS (blue cards) BUSULFAN CARMUSTINE (BCNU) CYCLOPHOSPHAMIDE DACARBAZINE LOMUSTINE (CCNU) MECHLORETHAMINE MELPHALAN THIOTEPA NATURAL
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationAccess to Cancer Drugs in Canada: Looking Beyond Coverage Decisions
Data Matters Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions Accès aux médicaments pour traiter le cancer au Canada : voir au-delà des décisions concernant la couverture Ro ge r C h
More informationOVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationCancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
More informationCCC Chemotherapy Protocols V9.0
CCC Chemotherapy Protocols V9.0 General observations 3 Breast cancer 5 Gastrointestinal cancer Oesophagus 17 Gastric 19 Pancreas 22 Cholangiocarcinoma 24 Hepatocellular carcinoma 25 Neuroendocrine tumours
More informationGuidelines for the Management of Extravasation
Guidelines for the Management of Extravasation (Version 5.5-04 Nov 2016) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More informationCancer Drugs CANCER DRUGS NEW DRUGS AND INDICATIONS OVER THE PAST TEN YEARS
Cancer Drugs NEW DRUGS AND INDICATIONS OVER THE PAST TEN YEARS by KONG KHOO, ROSEMARY COLUCCI, DANIEL GILLESPIE, JAMES D. GOWING, PIERRE MAJOR, JOSEPH RAGAZ, DAVID SALTMAN, COLLEEN SAVAGE Development of
More informationVMG Pharmaceuticals Pvt. Ltd.
S. No. Product Name S trength Dos age form Oncology 1 A nastrazole 1 mg Tablets 2 Bicalutamide 50 mg Tablets 3 Bleomycin 15units,30units Injection 4 Bortezomib 3.5 mg Injection 5 Capecitabine 500 mg Tablets
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More informationIRB INDICATION Number ENROLLED
Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics
More informationTHE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES?
THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES? Alexandru ENIU, MD, PhD Chair, ESMO Global Policy Committee Department of Breast Tumors Cancer
More information2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous
Breast Cancer Patients: Begin on page 1, then skip to page 3 Lymphoma Patients: Begin on page 2 1. Newly diagnosed with Breast carcinoma Stage: (includes inflammatory breast and newly diagnosed recurrent
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationHazardous Medication List
Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling
More information